Harnessing pyrimidine as a building block for histone deacetylase inhibitors.
Arch Pharm (Weinheim)
; 356(10): e2300208, 2023 Oct.
Article
en En
| MEDLINE
| ID: mdl-37462396
ABSTRACT
Histone deacetylase (HDAC) inhibitors are well-established multifaceted bioactive agents against tumors and neurodegenerative disorders. Pyrimidine and its fused and substituted derivatives were employed as a surface recognition moiety of HDAC inhibitors. De facto, the literature was loaded with different success stories of pyrimidine-based HDAC inhibitors that garnered much interest. Provoked by our continuous interest in HDAC inhibitors, we summarized and elaborated on the successful harnessing of the pyrimidine scaffold in this regard. Furthermore, we dissect our perspective that may guide medicinal chemists for an effective future design of more active chemotherapeutic agents with potential clinical applications.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Inhibidores de Histona Desacetilasas
/
Antineoplásicos
Idioma:
En
Año:
2023
Tipo del documento:
Article